Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TuHURA Biosciences, Inc./NVKTRA · Entity 6601 | Chief Financial Officer | August 01, 2022 | August 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TuHURA Biosciences, Inc./NV
Report date August 01, 2022 · Filed August 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 277,273 |
Reported balance
After 2022-08-01 transaction · row 1
1 source rowRow 1 · 2022-08-01 · Grant · Acquired 240,087 · Balance 277,273 F1: The Reporting Person was granted 240,087 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.18 · Expires 2022-08-02 | Direct | 720,260 |
Reported balance
After 2022-08-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-01 · Grant · Acquired 720,260 · Balance 720,260 F2: The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 240,087 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023.
F2: The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2022 Filed Aug 3, 2022 20:30 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOption (right to buy) · Derivative | 720,260 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001493152-22-021172 · ownership.xml · derivative · entry 2 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720,260 Underlying: Common Stock · 720,260 shares Expires 2022-08-02 F2 · derivative.exercise_date: The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 20:30 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantCommon Stock | 240,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-021172 · ownership.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,273 F1 · shares: The Reporting Person was granted 240,087 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 21:09 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | PurchaseCommon Stock | 28,700 | $0.68 | $19,429.90 |
DisclosureSEC source: 0000899243-21-047520 · doc4.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,186 Read SEC document |
| April 29, 2021 Filed Apr 29, 2021 20:06 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | ConversionSeries B Convertible Preferred Stock · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-000630 · kintara_fm4apr292021.xml · derivative · entry 3 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00. F2 · kind: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock. F2 · derivative.expiration_date: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock. Read SEC document |
| April 29, 2021 Filed Apr 29, 2021 20:06 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | ConversionCommon Stock | 938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-21-000630 · kintara_fm4apr292021.xml · nonDerivative · entry 2 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock. F3 · price: Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00. Read SEC document |
| April 29, 2021 Filed Apr 29, 2021 20:06 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | OtherCommon Stock | 8 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-000630 · kintara_fm4apr292021.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,548 F1 · kind: The shares were issued as dividends to April 29, 2021 on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| March 31, 2021 Filed Mar 31, 2021 20:08 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | OtherCommon Stock | 22 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-000501 · kintara_fm4mar312021.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,540 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 13:00 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | OtherCommon Stock | 22 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-000042 · doc4.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,518 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| September 30, 2020 Filed Sep 30, 2020 20:06 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | OtherCommon Stock | 22 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-20-000998 · kintara_fm4sep302020.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,496 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:12 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 606,557 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000905718-20-000975 · kintara_fm4sep152020.xml · derivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606,557 Underlying: Common Stock · 606,557 shares Expires 2030-09-15 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021. Read SEC document |
| June 30, 2020 Filed Jun 30, 2020 20:17 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 22 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-016319 · ownership.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,474 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:17 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOption (Right to Buy) · Derivative | 57,170 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001213900-20-016319 · ownership.xml · derivative · entry 2 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,366 Underlying: Common Stock · 57,170 shares Expires 2029-09-05 F2 · kind: On September 5, 2019, the reporting person received options to purchase 57,170 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020. F3 · derivative.exercise_date: 1/6th of the options vested on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months which commenced on April 5, 2020. Read SEC document |
| March 31, 2020 Filed Mar 31, 2020 20:28 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 22 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-008229 · ownership.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,452 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 21:17 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 22 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-20-000018 · delmarph_fm4dec32019.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,430 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 20:14 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 22 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-19-000811 · delmarph_fm4sept302019.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,408 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 20:34 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 51,196 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000905718-19-000759 · delmarph_fm4sept52019.xml · derivative · entry 2 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,196 Underlying: Common Stock · 51,196 shares Expires 2029-09-05 F2 · derivative.exercise_date: 1/6th of the options vest on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 5, 2020. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 20:34 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 57,170 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000905718-19-000759 · delmarph_fm4sept52019.xml · derivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,170 Underlying: Common Stock · 57,170 shares Expires 2029-09-05 F1 · derivative.exercise_date: Subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the next annual meeting, 1/6th of the options vest on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 5, 2020. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 20:21 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 22 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-011882 · ownership.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,386 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · balance_after: On May 8, 2019, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 20:38 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 211 | $0.49 | $103.39 |
DisclosureSEC source: 0001213900-19-005506 · ownership.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,632 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 23:20 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 211 | $0.34 | $72.14 |
DisclosureSEC source: 0001213900-19-000055 · ownership.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,421 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 21:37 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001213900-18-015512 · ownership.xml · derivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-11-08 F1 · derivative.exercise_date: 1/6th of the options vest on May 8, 2019 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on June 8, 2019. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 20:08 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 211 | $3.20 | $675.20 |
DisclosureSEC source: 0001213900-18-013297 · ownership.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,210 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:41 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 211 | $3.20 | $675.20 |
DisclosureSEC source: 0001213900-18-008714 · ownership.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,999 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| March 30, 2018 Filed Apr 3, 2018 20:08 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 211 | $3.20 | $675.20 |
DisclosureSEC source: 0001213900-18-003991 · f4033018praill_delmar.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,788 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 21:55 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | ConversionExchangeable Shares · Derivative | 25,000 | $2.00 | $50,000.00 |
DisclosureSEC source: 0000905718-18-000012 · praill_form4dec312017.xml · derivative · entry 3 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exchangeable Shares are shares of a wholly-owned subsidiary of the Issuer that are exchangeable at any time for shares of common stock in the Issuer on the basis of one Exchangeable Share for one share of common stock. F2 · derivative.exercise_date: Exchangeable Shares are shares of a wholly-owned subsidiary of the Issuer that are exchangeable at any time for shares of common stock in the Issuer on the basis of one Exchangeable Share for one share of common stock. F2 · derivative.expiration_date: Exchangeable Shares are shares of a wholly-owned subsidiary of the Issuer that are exchangeable at any time for shares of common stock in the Issuer on the basis of one Exchangeable Share for one share of common stock. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 21:55 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | ConversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-18-000012 · praill_form4dec312017.xml · nonDerivative · entry 2 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Exchangeable Shares are shares of a wholly-owned subsidiary of the Issuer that are exchangeable at any time for shares of common stock in the Issuer on the basis of one Exchangeable Share for one share of common stock. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 21:55 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 211 | $3.20 | $675.20 |
DisclosureSEC source: 0000905718-18-000012 · praill_form4dec312017.xml · nonDerivative · entry 1 Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,577 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| October 05, 2017 Filed Oct 5, 2017 22:05 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | PurchaseCommon Stock | 17,500 | $0.85 | $14,910.00 |
DisclosureSEC source: 0001213900-17-010332 · f4100517praill_delmar.xml · nonDerivative · entry 1 Praill Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,366 Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 23:50 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 211 | $3.20 | $675.20 |
DisclosureSEC source: 0001213900-17-010206 · f4092917praill_delmarpharm.xml · nonDerivative · entry 1 Praill Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,866 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:30 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 211 | $3.20 | $675.20 |
DisclosureSEC source: 0001213900-17-007149 · f4063017praill_delmarpharma.xml · nonDerivative · entry 1 Praill Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,655 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 15:34 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | PurchaseCommon Stock | 4,167 | $3.60 | $15,001.20 |
DisclosureSEC source: 0001213900-17-006886 · f4062617praill_delmarpharma.xml · nonDerivative · entry 1 Praill Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,444 F1 · price: The Reporting Person purchased the shares in a private transaction for an aggregate purchase price of CDN $20,000. Reported price is based on exchange rate of 0.75. Read SEC document |
| June 06, 2017 Filed Jun 6, 2017 21:23 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | PurchaseCommon Stock | 9,500 | $2.10 | $19,950.00 |
DisclosureSEC source: 0001213900-17-006200 · f4060617praill_delmarpharma.xml · nonDerivative · entry 1 Praill Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,277 Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 22:16 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 211 | $3.20 | $675.20 |
DisclosureSEC source: 0001213900-17-003272 · f4033117praill_delmar.xml · nonDerivative · entry 1 Praill Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,777 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 21:25 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 37,400 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001213900-17-001713 · f4021717praill_delmarpharma.xml · derivative · entry 1 Praill Scott · CIK 0001332948 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,400 Underlying: Common Stock · 37,400 shares Expires 2027-02-17 F1 · derivative.exercise_date: The options vest in equal monthly installments over three years. Read SEC document |
| December 31, 2016 Filed Jan 3, 2017 18:54 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 211 | $3.20 | $675.20 |
DisclosureSEC source: 0001213900-17-000020 · f4123116praill_delmar.xml · nonDerivative · entry 1 Praill Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,566 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 22:20 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 211 | $3.20 | $675.20 |
DisclosureSEC source: 0001213900-16-017277 · f4100316praill_delmarpharma.xml · nonDerivative · entry 1 Praill Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,355 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.